SCHEMBL4862898

SCHEMBL4862898

O=CC(=NO)c1ccc(Br)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.44
▸ CES1 P23141 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ GSK3B P49841 2/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ OGG1 O15527 1/20 0.38
▸ LMNA P02545 2/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC10 Q969S8 1/20 0.36
▸ HDAC11 Q96DB2 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC9 Q9UKV0 1/20 0.36
▸ HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4452290 0.80 KDM1A (0.42) CES2HTTCA1CA2CYP1A2
SCHEMBL8388189 0.78 CES2 (0.39) CES2CES1HTTCA1CA2
SCHEMBL8388187 0.78 CES2 (0.39) CES2CES1HTTCA1CA2
SCHEMBL5469786 0.78 CES2 (0.44) CES2CES1CA1CA2GSK3B
SCHEMBL5464455 0.78 ALDH1A1 (0.45) CES2CES1HTTGSK3BLMNA
SCHEMBL5464534 0.78 CES2 (0.44) CES2CES1CA1CA2CYP1A2
SCHEMBL5485249 0.77 ALDH1A1 (0.50) CES2CES1HTTCA1CA2
SCHEMBL11381140 0.74 ALDH1A1 (0.48) HTTRAB9AMAPTALDH1A1HPGD
SCHEMBL11388311 0.74 HDAC1 (0.46) HTTCA1CA2CYP1A2LMNA
SCHEMBL3045890 0.70 ALDH1A1 (0.58) CES2CES1CA1CA2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470713-B2 Imidazole based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-30 — — US disclosed
EP-1175410-B1 PESTICIDAL TRIAZINE DERIVATIVES NOVARTIS AG (CH) 2005-12-07 — — EP disclosed
US-20050187218-A1 Imidazole based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-08-25 — — US disclosed
US-6723720-B2 PHENYL-SUBSTITUTED 1,2,4-TRIAZINES, ESPECIALLY FOR CONTROLLING FLEAS NOVARTIS ANIMAL HEALTH US, INC. 2004-04-20 — — US disclosed
US-20030036544-A1 Pesticidal triazine-derivatives NOVARTIS ANIMAL HEALTH US, INC. 2003-02-20 — — US disclosed
EP-1175410-A1 PESTICIDAL TRIAZINE DERIVATIVES Syngenta Participations AG (CH) 2002-01-30 — — EP disclosed
WO-2000066568-A1 PESTICIDAL TRIAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2000-11-09 — — WO disclosed
US-4293552-A Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas ELI LILLY AND COMPANY (US) 1981-10-06 — — US disclosed
US-4160834-A INSECTICIDES ELI LILLY AND COMPANY (US) 1979-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187218-A1 Imidazole based kinase inhibitors MAP3K19, MAP3K1, ABL1 CES2 4498/4885CES1 3373/4885HTT 4825/4885
US-20030036544-A1 Pesticidal triazine-derivatives DDT, CYCS, TUBA3C CES2 201/4885CES1 194/4885HTT 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback